NCT06150651已完成1 期
Safety/Phase I Study of PiggyBac Transposon Mediated Chimeric Antigen Receptor T Cells Targeting CD-19 in Thai Patients With Refractory Systemic Lupus Erythematosus
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Safety of PiggyBac transposon-mediated CAR T-cell infusion targeting CD19 in adult patients with refractory SLE.
研究概览
简要总结
A Phase 1 clinical trial to evaluate the safety and efficacy of PiggyBac transposon-mediated Chimeric Antigen Receptor(CAR) T-cells targeting CD19 in refractory Systemic Lupus Erythematosus (SLE) patients who have not responded to standard immunosuppressive treatments.
详细描述
This is a single-institution phase I study in adults with refractory SLE. Autologous Peripheral Blood Mononuclear Cells will be transduced with a chimeric antigen receptor targeting the B-cell surface antigen CD19 using the PiggyBac Transposon system. Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide, followed by the infusion of 1x10^6 cells/kg CD-19 CAR T-cells. Subjects will be evaluated post-treatment for toxicity, SLE disease activity, and the persistence of CAR-expressing T cells in vivo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 60 years.
- •Diagnosis of Systemic Lupus Erythematosus (SLE), as defined by the American College of Rheumatology (ACR) 1997 criteria, The Systemic Lupus International Collaborating Clinics (SLICC) criteria, or the European Alliance of Associations for Rheumatology (EULAR)/ACR classification.
- •Refractory SLE, defined by one or more of the following:
- •3.1 Persistently active SLE requiring ongoing maintenance therapy (if not contraindicated) with:
- •Antimalarial drug.
- •Either mycophenolate (minimum daily dose of 1500 mg) or azathioprine (minimum daily dose of 1.5 mg/kg).
- •Patients must also need a minimum daily dose of 7.5 mg prednisolone for lower disease activity maintenance, or have a SLEDAI score of 8 or higher.
- •3.2 Biopsy-proven proliferative lupus nephritis after two standard induction therapies, including intravenous cyclophosphamide (cumulative dose of at least 1.5 g) and mycophenolate mofetil (administered for a minimum of 3 months), unless contraindicated.
- •3.3 Worsening of biopsy-proven lupus nephritis (activity index > 6 and chronicity index < 6 within 6 months), indicated by increased proteinuria and/or decreased estimated glomerular filtration rate, despite treatment with high-dose corticosteroids (prednisolone at least 0.7 mg/kg/day or equivalent) and either mycophenolate mofetil or cyclophosphamide for a minimum of 14 days.
- •Ability to understand and willingness to sign a written informed consent document.
- •Participants of child-bearing or child-fathering potential must agree to practice birth control from enrollment until four months after receiving CAR T-cell infusion.
排除标准
- •Pregnant or breastfeeding women.
- •History of active malignancy, excluding non-melanoma skin cancer and carcinoma in situ (e.g., cervix, bladder, breast).
- •History of vital organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities, cirrhosis, or psychiatric illness/social situations that limit compliance with study requirements.
- •Any other clinically significant disease history or current disease that, in the judgment of the research physician, may pose a risk to the safety of the subjects or interfere with the research procedure, or the evaluation of safety and efficacy.
- •Serologic status indicating active HIV, hepatitis B, or C infection. Participants positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative PCR prior to enrollment.
- •History of severe adverse drug reaction to Cyclophosphamide or Fludarabine.
- •Received a live vaccine within 30 days prior to CAR-T cell infusion.
- •eGFR CKD-EPI < 30 ml/min/1.73m^
- •Participation in other clinical investigations during the study period.
- •Prior receipt of CAR-T cell therapy outside this protocol.
结局指标
主要结局
Safety of PiggyBac transposon-mediated CAR T-cell infusion targeting CD19 in adult patients with refractory SLE.
时间窗: Up to 28 days after CD-19 CAR-T cell infusion
The incidence of adverse events assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0
次要结局
- Disease activity of SLE(3, 6, and 12 months after CD-19 CAR-T cell infusion)
- Partial response rate of lupus nephritis(3, 6, and 12 months after CD-19 CAR-T cell infusion)
- Complete response rate of lupus nephritis(3, 6, and 12 months after CD-19 CAR-T cell infusion)
研究者
Wonngarm Kittanamongkolchai, MD
Principle Investigator
Chulalongkorn University
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Safety/Phase I study of PiggyBac transposon mediated Chimeric Antigen Receptor T cells targeting CD-19 in Thai patients with relapsed or refractory B-cell acute lymphoblastic leukemia and lymphomaAcute Lymphoblastic LeukemiaRelapse Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRelapse Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin LymphomaTCTR20210818003King Chulalongkorn Memorial Hospital, Thai Red Cross Society12
招募中
1 期
Phase I study of piggyBac transposon mediated chimeric antigen receptor gene modified T cells for CD19 positive acute lymphoblastic leukemiarefractory/relapsed CD19 positive acute lymphoblastic leukemiaJPRN-UMIN000030984agoya University12
终止
1 期
Safety Study: Combined Modality Treatment for Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT00265603Atlantic Health System16
终止
1 期
Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial IschemiaHeart FailureNCT01354678Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health15
已完成
不适用
Gene-activated Bone Substitute for Maxillofacial Bone RegenerationBone CystsBone AtrophyBone DeformityBone FractureBone LossTooth LossNCT03076138Histograft Co., Ltd.20